-+ 0.00%
-+ 0.00%
-+ 0.00%

Mesoblast acquires CAR-MSC platform startup, secures exclusive Mayo Clinic license

PUBT·04/15/2026 00:11:17
Listen to the news
Mesoblast acquires CAR-MSC platform startup, secures exclusive Mayo Clinic license
  • Mesoblast acquired a startup holding an exclusive worldwide license to patented CAR technology for genetically engineered mesenchymal stromal cell (MSC) products.
  • Platform, developed at Mayo Clinic, is intended to improve MSC targeting to inflamed tissue to boost potency in inflammatory diseases.
  • Near-term development focus includes CAR-MSC candidates for ulcerative colitis or Crohn’s disease.
  • Mesoblast also plans CAR-MSC engineered to express CD19 for lupus nephritis and other B-cell autoimmune diseases.
  • Consideration was paid via issuance of ASX ordinary shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604142010PRIMZONEFULLFEED9690062) on April 15, 2026, and is solely responsible for the information contained therein.